Ultragenyx

Ultragenyx is facing a securities fraud class action lawsuit for allegedly making false and misleading statements regarding its drug setrusumab and its Phase III Orbit study. This could lead to significant financial penalties and reputational damage for the company.

Ultragenyx is facing a class action lawsuit alleging that it made false and misleading statements regarding its drug setrusumab and its Phase III Orbit study. This could negatively impact its stock price and reputation.

Ultragenyx is facing a class action lawsuit alleging that it made materially false and misleading statements regarding its Phase III Orbit and Cosmic Studies for setrusumab. This could lead to financial penalties and reputational damage for the company.

Ultragenyx is facing a class action lawsuit due to alleged securities fraud, following significant drops in its stock price after failed clinical trials for UX143 (setrusumab). The company's stock fell 25.11% and 42.32% on two separate occasions due to negative news.

Ultragenyx announced that the U.S. United States===Food and Drug Administration accepted its Biologics License Application for UX111, a gene therapy for Sanfilippo syndrome Type A. This brings the company closer to potentially launching the first approved therapy for this rare disease, which could significantly boost its market position and revenue.